UroToday1d
SCS AUA 2024: Pelvic Exenteration and Urologic Complications: A 90-Day Audit of the Practice at a Single Tertiary Level Medical Center
(UroToday.com) The 2024 South Central AUA annual meeting included a session on lower genitourinary tract cancer, featuring a presentation by Anish Patel discussing 90-day urologic complications from ...
UroToday2d
SCS AUA 2024: Does the Use of Continuous Bladder Irrigation After TURBT Increase the Risk of Complications?
(UroToday.com) The 2024 South Central AUA annual meeting included a session on lower genitourinary tract cancer, featuring a presentation by Clare Weiland discussing whether the use of continuous ...
UroToday2d
SCS AUA 2024: Financial Toxicity in Testicular Cancer Treatment, Validated Questionnaire Correlated Software Cost Modeling
The 2024 South Central AUA annual meeting included a session on lower genitourinary tract cancer, featuring a presentation by Dr. Peter Sullivan discussing financial toxicity in testicular cancer ...
UroToday2d
SCS AUA 2024: Multiparametric MRI in the Evaluation of Small Renal Masses
(UroToday.com) The 2024 South Central AUA annual meeting included an endourology session, featuring a presentation by Dr. Jeffrey Cadeddu discussing multiparametric MRI in the evaluation of small ...
UroToday3d
SCS AUA 2024: Efficacy of Intravesical Nadofaragene Firadenovec-VNCG for Patients with BCG-Unresponsive NMIBC: 36-Month Follow-Up from a Phase 3 Trial
(UroToday.com) The 2024 South Central AUA annual meeting included a session on bladder cancer, featuring a presentation by Dr. Yair Lotan discussing 36-month follow-up from a phase 3 trial assessing ...
UroToday3d
SCS AUA 2024: Should Veterans be Classified as High Risk for Prostate Cancer Screening: A Review of the Current Literature
(UroToday.com) The 2024 South Central AUA annual meeting included a session on prostate cancer, featuring a presentation by Dr. Gal Saffati discussing a systematic review regarding whether veterans ...
UroToday3d
SCS AUA 2024: Can the PSMA PET SUVmax Predict High Risk Pathology and High Risk Disease? A Single Center Prospective Disease
SUVmax cut point of 9 is associated with a: 33-fold higher risk of high risk pathology in radical prostatectomy specimens with a PPV of 81% 24-fold higher risk of high risk disease features in radical ...
UroToday3d
SCS AUA 2024: Elucidating the Response Rates to Additional BCG: Implications for Clinical Trial Design
The 2024 South Central AUA annual meeting included the Sushil Lacy manuscript competition, featuring a presentation by Dr. Amanda Myers discussing the elucidation of response rates to additional BCG ...